MA41140A - Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg - Google Patents

Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg

Info

Publication number
MA41140A
MA41140A MA041140A MA41140A MA41140A MA 41140 A MA41140 A MA 41140A MA 041140 A MA041140 A MA 041140A MA 41140 A MA41140 A MA 41140A MA 41140 A MA41140 A MA 41140A
Authority
MA
Morocco
Prior art keywords
quinazoline
dioxo
sulfonamide derivatives
parg inhibitors
parg
Prior art date
Application number
MA041140A
Other languages
English (en)
Inventor
Niall M Hamilton
James R Hitchin
Colin Hutton
Allan Jordan
Alison E Mcgonagle
Kate Mary Smith
Ian Waddell
Bohdan Waszkowycz
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of MA41140A publication Critical patent/MA41140A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA041140A 2014-12-12 2015-12-10 Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg MA41140A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201422098 2014-12-12

Publications (1)

Publication Number Publication Date
MA41140A true MA41140A (fr) 2017-10-17

Family

ID=54937266

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041140A MA41140A (fr) 2014-12-12 2015-12-10 Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg

Country Status (15)

Country Link
US (1) US10239843B2 (fr)
EP (1) EP3230273A1 (fr)
JP (1) JP2017537137A (fr)
KR (1) KR20170093967A (fr)
CN (1) CN107207467A (fr)
AU (1) AU2015359082A1 (fr)
BR (1) BR112017012402A2 (fr)
CA (1) CA2969296A1 (fr)
IL (1) IL252575A0 (fr)
MA (1) MA41140A (fr)
MX (1) MX2017007478A (fr)
RU (1) RU2017124425A (fr)
SG (1) SG11201704686UA (fr)
WO (1) WO2016092326A1 (fr)
ZA (1) ZA201704382B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
WO2016169906A1 (fr) 2015-04-21 2016-10-27 Glaxosmithkline Intellectual Property Development Limited Dérivés de 2,4-dioxo-1,2-dihydropyrido[3,4-d]pyrimidine
IL291436B1 (en) * 2019-09-20 2026-07-01 Ideaya Biosciences Inc History of indole and indazole sulfonamido 4-mutates as PARG inhibitors
WO2022138812A1 (fr) 2020-12-24 2022-06-30 モジュラス株式会社 Composé de tétrahydrothiénopyridinesulfonamide
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
CA3225500A1 (fr) 2021-10-04 2023-04-13 Ulrich Luecking Composes inhibiteurs de parg
IL311851A (en) * 2021-10-04 2024-05-01 Forx Therapeutics Ag PARG inhibitory compounds
CA3251360A1 (fr) 2022-02-14 2023-08-17 Arase Therapeutics Inc. Inhibiteurs de parg
EP4488275A4 (fr) 2022-03-04 2025-07-23 Shanghai Yingli Pharm Co Ltd Composé contenant une structure cyclique hétéroaromatique à cinq chaînons, composition pharmaceutique et utilisation associées
WO2023175184A1 (fr) 2022-03-17 2023-09-21 Forx Therapeutics Ag Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés comme inhibiteurs de parg pour le traitement du cancer
WO2023175185A1 (fr) 2022-03-17 2023-09-21 Forx Therapeutics Ag Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés en tant qu'inhibiteurs de parg pour le traitement du cancer
PL4496795T3 (pl) 2022-03-23 2026-07-20 Ideaya Biosciences, Inc. Związki indazolowe podstawione piperazyną jako inhibitory parg
IL316261A (en) * 2022-04-28 2024-12-01 Danatlas Pharmaceuticals Co Ltd Tricyclic and heterocyclic derivatives, preparations and uses thereof
TW202409036A (zh) 2022-05-17 2024-03-01 美商858療法股份有限公司 Parg抑制劑
AU2023310489A1 (en) * 2022-07-19 2025-02-13 Evopoint Biosciences Co., Ltd. Sulfur-containing heteroaromatic ring compound, pharmaceutical composition thereof, and use thereof
EP4311829A1 (fr) 2022-07-28 2024-01-31 Nodus Oncology Limited Dérivés d'hétéroaryl sulfonamide bicyclique substitués pour le traitement du cancer
IL320031A (en) 2022-10-03 2025-06-01 Forx Therapeutics Ag Parg inhibitory compound
WO2024173524A1 (fr) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Composés benzimidazoles à substitution hétéroaryle
WO2024173453A1 (fr) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Composés d'imidazopyridine à substitution hétéroaryle
WO2024173530A1 (fr) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Composés pyrazolo/imidazo pyridine à substitution hétéroaryle
WO2024173514A1 (fr) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Composés d'imidazopyridine à substitution amide et ester
WO2024209035A1 (fr) 2023-04-05 2024-10-10 Forx Therapeutics Ag Composés inhibiteurs de parg
WO2024254990A1 (fr) 2023-06-16 2024-12-19 上海璎黎药业有限公司 Composé ayant une structure cyclique hétéroaromatique, composition pharmaceutique associée et son utilisation
WO2025046148A1 (fr) 2023-09-01 2025-03-06 Forx Therapeutics Ag Nouveaux inhibiteurs de parg
TW202517256A (zh) * 2023-09-14 2025-05-01 中國大陸商再鼎醫藥（上海）有限公司 稠合雙環雜芳基作為ｐａｒｇ抑制劑及其用途
KR20260084620A (ko) 2023-10-03 2026-06-05 포알엑스 테라퓨틱스 아게 Parg 억제 화합물
WO2025093755A1 (fr) 2023-11-01 2025-05-08 Forx Therapeutics Ag Nouveaux inhibiteurs de parg
WO2025111339A1 (fr) * 2023-11-21 2025-05-30 858 Therapeutics, Inc. Traitement du cancer avec un inhibiteur de parg
WO2025133396A1 (fr) 2023-12-22 2025-06-26 Forx Therapeutics Ag Nouveaux inhibiteurs de parg bicyclo hétéroaryles
WO2025165942A1 (fr) * 2024-01-31 2025-08-07 Synnovation Therapeutics, Inc. Composés tricycliques utilisés en tant qu'inhibiteurs de parg
WO2025245087A1 (fr) * 2024-05-23 2025-11-27 Synnovation Therapeutics, Inc. Composés hétérocycliques utilisés en tant qu'inhibiteurs de parg
WO2026022150A1 (fr) 2024-07-22 2026-01-29 Forx Therapeutics Ag Composés inhibiteurs de parg
WO2026062066A1 (fr) 2024-09-17 2026-03-26 Forx Therapeutics Ag Composés induisant une dégradation de parg
WO2026107046A1 (fr) * 2024-11-13 2026-05-21 Synnovation Therapeutics, Inc. Composés hétérocycliques utilisés en tant qu'inhibiteurs de parg

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1157858A (fr) * 1979-12-03 1983-11-29 Ikuo Ueda Derives de quinazoline
DE19927415A1 (de) 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
US7009052B2 (en) * 2003-03-20 2006-03-07 Warner Lambert Company Llc Sulfonamide derivatives
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
WO2005080399A1 (fr) 2004-02-24 2005-09-01 Japan Tobacco Inc. Composés hétérotétracycliques fondus et utilisation de ces composés en tant qu'inhibiteurs par polymérase du virus de l’hépatite c
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
WO2007014226A2 (fr) * 2005-07-26 2007-02-01 The Board Of Trustees Of The University Of Illinois Composes pour le traitement de neurodegenerescence et d'accident cerebro-vasculaire
NZ568910A (en) 2006-01-24 2011-04-29 Lilly Co Eli Indole sulfonamide modulators of progesterone receptors
WO2007107469A1 (fr) * 2006-03-20 2007-09-27 F. Hoffmann-La Roche Ag Procédés d'inhibition des protéines kinase btk et syk
WO2009047255A1 (fr) * 2007-10-09 2009-04-16 Ucb Pharma, S.A. Composés hétérobicycliques utiles comme antagonistes du récepteur h4 de l'histamine
RU2011105810A (ru) 2008-07-17 2012-08-27 Асахи Касеи Фарма Корпорейшн (Jp) Азотсодержащие бициклические гетероциклические соединения
CN101429191B (zh) 2008-11-03 2012-05-23 中国药科大学 取代的四氢异喹啉衍生物的用途
JP2013526484A (ja) 2010-05-07 2013-06-24 グラクソ グループ リミテッド キナーゼ阻害剤としてのアミノ‐キノリン
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
EP2627648A1 (fr) * 2010-09-16 2013-08-21 Novartis AG INHIBITEURS DE LA 17a-HYDROXYLASE/C17,20-LYASE
CA2817460A1 (fr) * 2010-12-17 2012-06-21 F. Hoffmann-La Roche Ag Composes heterocycliques azotes 6,6-condenses substitues et leurs utilisations
EP2471363A1 (fr) * 2010-12-30 2012-07-04 Bayer CropScience AG Utilisation d'acides aryl-, hétéroaryl- et benzylsulfonaminés, d'esters d'acide aminé, d'amides d'acide aminé et carbonitrile ou leurs sels pour l'augmentation de la tolérance au stress dans des plantes
WO2013027168A1 (fr) * 2011-08-22 2013-02-28 Pfizer Inc. Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de bromodomaine
WO2013067300A1 (fr) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Méthode de traitement
JP2014106019A (ja) 2012-11-26 2014-06-09 Stack Electronics Co Ltd プローブ
HK1217649A1 (zh) * 2012-12-27 2017-01-20 德雷克塞尔大学 針對hbv感染的新型抗病毒劑
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg

Also Published As

Publication number Publication date
ZA201704382B (en) 2019-09-25
JP2017537137A (ja) 2017-12-14
SG11201704686UA (en) 2017-07-28
CA2969296A1 (fr) 2016-06-16
CN107207467A (zh) 2017-09-26
RU2017124425A (ru) 2019-01-14
US20180016242A1 (en) 2018-01-18
WO2016092326A1 (fr) 2016-06-16
KR20170093967A (ko) 2017-08-16
EP3230273A1 (fr) 2017-10-18
IL252575A0 (en) 2017-07-31
BR112017012402A2 (pt) 2017-12-26
US10239843B2 (en) 2019-03-26
MX2017007478A (es) 2018-05-04
AU2015359082A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
ZA201704382B (en) 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of parg
HUE058009T2 (hu) 1,3-Tiazol-2-il szubsztituált benzamid-származékok
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
LT3190113T (lt) Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
DK3319956T3 (da) Substituerede oxopyridinderivater
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
DK3094631T3 (da) Pyrimidinyloxybenzenderivater som herbicider
IL252089A0 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
EP3457851A4 (fr) Dérivés de sobétirome
EP3283171A4 (fr) Dérivés d'amphotéricine b
IL250038A0 (en) 4,5 - dehydroisoxazole derivatives used as nampt inhibitors
DK3153508T3 (da) Naphthofuranderivater til anvendelse som anticancermidler
EP2953470A4 (fr) Purines 2,6,7 substituées utilisées en tant qu'inhibiteurs de hdm2
LT3273947T (lt) Kompozicija, skirta akių sveikatai
HUE054815T2 (hu) 3,5-Difenil-diazol vegyületek vízoldható származékai
SMT202200179T1 (it) Composizione acquosa oftalmica.
LT3347360T (lt) Junginiai, naudingi ror-gama-t slopinimui
DK3319970T3 (da) Pyrido-oxazinonderivater som tnap-hæmmere
LT3341380T (lt) Chromono oksimo darinys, prasiskverbiantis į smegenis, skirtas levadopa sukeltos diskinezijos gydymui
LT3389633T (lt) Farmacinės kompozicijos, apimančios fenilaminopirimidino darinį